Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT01154439 Completed - Leukemia Clinical Trials

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

AML1208
Start date: October 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving everolimus together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin in treating older patients with newly diagnosed acute myeloid leukemia.

NCT ID: NCT01150669 Completed - Clinical trials for Childhood Acute Lymphoblastic Leukemia

Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia

Start date: July 2010
Phase: N/A
Study type: Observational

This research study is studying lestaurtinib with or with chemotherapy in samples from young patients with leukemia. Studying the effects of lestaurtinib with or without chemotherapy in cell samples from patients with cancer in the laboratory may help doctors learn more about the effects of this treatment on cancer cells. It may also help doctors identify biomarkers related to cancer.

NCT ID: NCT01150058 Completed - Leukemia Clinical Trials

Drug Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia

Start date: November 2010
Phase: N/A
Study type: Observational

RATIONALE: Studying cell samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer PURPOSE: This research study is studying drug biomarkers in cell samples from patients with acute myeloid leukemia.

NCT ID: NCT01149915 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the maximum tolerated dose, dose limiting toxicity, safety and tolerability of TH-302 in patients with acute leukemias, advanced phase chronic myelogenous leukemia (CML), high risk myelodysplastic syndromes, advanced myelofibrosis or relapsed/refractory chronic lymphocytic leukemia (CLL).

NCT ID: NCT01149408 Completed - Clinical trials for Acute Myeloid Leukemia

Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients

Start date: February 2011
Phase: Phase 1
Study type: Interventional

The study aims at determining the feasibility of using maintenance Decitabine therapy following remission induction and consolidation in elderly Acute Myeloid Leukemia patients who are fit for aggressive therapy. Primary: Safety and tolerability of the decitabine regimen in the post remission state. Secondary: 1. Disease-free survival - To determine the one-year disease-free survival in elderly patients with acute myeloid leukemia (AML) in complete remission treated with Decitabine as post-consolidation maintenance therapy. 2. Overall survival

NCT ID: NCT01147939 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

CLAVELA
Start date: June 2010
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of elacytarabine versus investigator's choice treatment in patients with relapsed or refractory acute myeloid leukemia (AML).

NCT ID: NCT01146977 Recruiting - Clinical trials for Acute Myeloid Leukemia

Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)

CBF(+)AML
Start date: January 2010
Phase: Phase 2
Study type: Interventional

Evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1).

NCT ID: NCT01146262 Active, not recruiting - Clinical trials for Acute Myelogenous Leukemia

Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)

CD lam
Start date: November 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Dendritic cells vaccinations are increasingly used in order to develop antitumoral immune response. This will be a Phase 2 trial using autologous dendritic cells pulsed with leukemic apoptotic corpse in acute myelogenous leukemia (AML) patients in first or second Complete remission (CR).

NCT ID: NCT01146223 Completed - Clinical trials for Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia

Start date: September 2009
Phase: N/A
Study type: Observational

This research study is studying biomarkers in patients with acute promyelocytic leukemia. Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and about biomarkers related to cancer.

NCT ID: NCT01146210 Recruiting - Clinical trials for Chronic Myelomonocytic Leukemia

Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Start date: October 2009
Phase: N/A
Study type: Observational

This research study is studying identification of de novo Fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia. Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to Fanconi anemia in patients with acute myeloid leukemia.